BACKGROUND: Ceramide (Cer) and sphingosine (Sph) interfere with critical cellular functions relevant for @entity5 progression and cell survival. While Cer has already been investigated as a potential drug target for @entity706 treatment, information about the potency of sphingosine is scarce. The aim of this study therefore was to evaluate Sph and its synthetic stereoisomer L-threo-sphingosine (Lt-Sph) as potential treatment options for @entity146 . METHODS: @entity1892 ( @entity1892 ) cell lines were incubated with Sph and Lt-Sph and consequently analysed by flow cytometry (FACS), enzyme-linked immunosorbent assay (ELISA), liquid chromatography coupled to triple-quadrupole mass spectrometry (LC/MS/MS), electron microscopy, and Western blot. RESULTS: Sph induced cell death and blocked cell growth independently of S1P receptors in different @entity1892 cell lines. Three different modes of Sph-mediated cell death were observed: Apoptosis, autophagy, and @entity7131 ( @entity7131 ) inhibition. Generation of pro-apoptotic Cer accounted only for a minor portion of the apoptotic rate. CONCLUSION: Sph and its analogues could evolve as alternative treatment options for @entity146 via @entity7131 inhibition, apoptosis, and autophagy. These physiological responses induced by different intracellular signalling cascades (phosphorylation of JNK, @entity12982 cleavage, LC3-II accumulation) identify Sph and analogues as potent cell death inducing agents.    2014 S. Karger AG, Basel.

Evaluating sphingosine and its analogues as potential alternatives for aggressive XXXX treatment.

@entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive lymphomas'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity7131 :: ('MESH:D020151', 'Disease') :: ['protein kinase C', 'PKC'] @entity12982 :: ('142', 'Gene') :: ['PARP'] @entity1892 :: ('MESH:D016393', 'Disease') :: ['DLBCL', 'Diffuse large B cell lymphoma']
@entity706 :: (MESH:D008223,Disease) :: ['lymphoma']
